NEW ORLEANS, April 28, 2014 /PRNewswire/ -- Former Attorney
General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of
Kahn Swick & Foti, LLC ("KSF") are investigating the proposed
sale of Furiex Pharmaceuticals, Inc. ("Furiex" or the "Company")
(NASDAQ: FURX) to Forest Laboratories, Inc. (NYSE:
FRX). Under the terms of the proposed transaction,
shareholders of Furiex will receive only $95.00 per share – plus up to $30.00 per share in the form of a Contingent
Value Right that may be payable based on the status of eluxadoline,
Furiex's lead product, as a controlled drug following approval –
for each share of Furiex common stock that they own. KSF is
seeking to determine whether this consideration and the process
that led to it are adequate, or whether the consideration
undervalues the Company.
If you believe that this transaction undervalues the Company
and/or if you would like to discuss your legal rights regarding the
proposed sale, you may, without obligation or cost to you, e-mail
or call KSF Managing Partner Lewis S. Kahn
(lewis.kahn@ksfcounsel.com) or associate Michael J. Palestina
(michael.palestina@ksfcounsel.com) toll free at any time at
855-768-1857.
To learn more about KSF, whose partners include the Former
Louisiana Attorney General, visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
206 Covington St.
Madisonville, LA 70447
SOURCE Kahn Swick & Foti, LLC